Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.050
-0.450 (-30.00%)
At close: Mar 27, 2026, 4:00 PM EDT
0.9800
-0.0700 (-6.67%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Alzamend Neuro Employees
As of January 31, 2026, Alzamend Neuro had 6 total employees, including 4 full-time and 2 part-time employees. The number of employees decreased by 1 or -14.29% compared to the same quarter last year.
Employees
6
Change
-1
Growth
-14.29%
Revenue / Employee
n/a
Profits / Employee
-$1,257,455
Market Cap
3.99M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jan 31, 2026 | 6 | -1 | -14.29% | 4 | 2 |
| Oct 31, 2025 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2025 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2025 | 7 | 0 | - | 4 | 3 |
| Jan 31, 2025 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2024 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2024 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2024 | 7 | 0 | - | 4 | 3 |
| Jan 31, 2024 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2023 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2023 | 7 | -1 | -12.50% | 4 | 3 |
| Apr 30, 2023 | 7 | -1 | -12.50% | 4 | 3 |
| Jan 31, 2023 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2022 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2022 | 8 | 2 | 33.33% | 4 | 4 |
| Apr 30, 2022 | 8 | 2 | 33.33% | 4 | 4 |
| Jan 31, 2022 | 7 | 3 | 75.00% | 3 | 4 |
| Oct 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| VivoSim Labs | 14 |
| Biodexa Pharmaceuticals | 13 |
| Genprex | 13 |
| Azitra | 12 |
| Revelation Biosciences | 9 |
| Purple Biotech | 9 |
| Akari Therapeutics, | 9 |
| Indaptus Therapeutics | 7 |
ALZN News
- 1 day ago - Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions - PRNewsWire
- 11 days ago - Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital - PRNewsWire
- 4 months ago - Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital - PRNewsWire
- 8 months ago - Alzamend Neuro to Present at the 2025 Military Health System Research Symposium - GlobeNewsWire
- 8 months ago - Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs - GlobeNewsWire
- 10 months ago - Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule - GlobeNewsWire
- 10 months ago - Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire
- 11 months ago - Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire